Metabolic & Cardiometabolic
PCSK9 inhibitors (evolocumab, alirocumab) decreases LDL cholesterol (~50-60%)
In plain terms: Do PCSK9 inhibitors like evolocumab and alirocumab substantially lower LDL cholesterol?
Part of: 💊 PCSK9 inhibitors
Yes, unequivocally — monoclonal PCSK9 antibodies cut LDL cholesterol by roughly 50-60% on top of statins, one of the most reproducible drug effects in lipidology.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Robinson 2015 (ODYSSEY LONG TERM) venue: N Engl J Med · N Engl J Med | RCT | supports | high | ODYSSEY LONG TERM: alirocumab 150mg in 2,341 high-risk patients lowered LDL 62% vs placebo at week 24, sustained over 78 weeks. |
| Koren 2014 (MENDEL-2) venue: J Am Coll Cardiol · J Am Coll Cardiol | RCT | supports | high | MENDEL-2: evolocumab monotherapy (no statin) lowered LDL 55-57% vs placebo and 38-40% vs ezetimibe in 614 low-risk patients. |
| Toth 2017 · J Am Heart Assoc | meta-analysis | supports | high | Network meta-analysis: evolocumab gave the largest LDL reductions (~54-75% by background) versus ezetimibe and placebo across therapy combinations. |
| Sabatine 2015 (OSLER) venue: N Engl J Med · N Engl J Med | RCT | supports | high | OSLER open-label extensions: evolocumab lowered LDL 61% (median 120→48 mg/dL) in 4,465 patients; consistent with phase 2/3 program. |
| Schwartz 2018 (ODYSSEY OUTCOMES) venue: N Engl J Med · N Engl J Med | RCT | supports | high | ODYSSEY OUTCOMES: alirocumab in 18,924 post-ACS patients on statins lowered LDL ~55% at 4 months and reduced major CV events (HR 0.85). |
| Raal 2015 (RUTHERFORD-2) venue: Lancet · Lancet | RCT | supports | high | RUTHERFORD-2: evolocumab in 331 heterozygous FH patients on statins lowered LDL 59-66% vs placebo — effective even in genetic hypercholesterolemia. |
| Guedeney 2019 · Eur Heart J | meta-analysis | supports | high | Meta-analysis of alirocumab and evolocumab RCTs showed large LDL-C reductions with corresponding decreases in cardiovascular events. |
| Sabatine 2017 (FOURIER) venue: N Engl J Med · N Engl J Med | RCT | supports | high | FOURIER: evolocumab in 27,564 statin-treated ASCVD patients lowered LDL 59% (median 92→30 mg/dL) and cut CV events 15%; definitive large-scale LDL effect. |
| Blom 2014 (DESCARTES) venue: N Engl J Med · N Engl J Med | RCT | supports | high | DESCARTES: 52-week evolocumab lowered LDL ~57% vs placebo in 901 patients on background therapy — durable year-long reduction. |
| Navarese 2015 · Ann Intern Med | meta-analysis | supports | high | Meta-analysis of 24 trials (10,159 patients): PCSK9 antibodies lowered LDL ~47% and, in pooled data, reduced all-cause mortality — independent confirmation. |
| Burnett 2025 · J Cardiovasc Pharmacol | meta-analysis | supports | moderate | Updated network meta-analysis of 20 trials confirms PCSK9 monoclonal antibodies produce among the largest LDL-C reductions of non-statin therapies. |
| Robinson 2014 (LAPLACE-2) venue: JAMA · JAMA | RCT | supports | high | LAPLACE-2: evolocumab added to moderate/high-intensity statins lowered LDL 63-75% vs placebo across 2,067 patients; beat ezetimibe add-on. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.